Literature DB >> 29264093

Bilaterally dilated episcleral vessels in patients with heritable pulmonary arterial hypertension.

Meri Watanabe1, Shinji Makino1, Hiroto Obata1.   

Abstract

Entities:  

Keywords:  episcleral vessel; heritable pulmonary arterial hypertension; intraocular pressure

Year:  2017        PMID: 29264093      PMCID: PMC5729320          DOI: 10.1002/jgf2.89

Source DB:  PubMed          Journal:  J Gen Fam Med        ISSN: 2189-7948


× No keyword cloud information.
A 51‐year‐old woman complaining of blurry vision in her left eye for the previous 6 months was referred to our hospital. Her medical history was indicative of heritable pulmonary arterial hypertension (HPAH) since when she was in her 30s, which was confirmed on the basis of a mutation in the gene encoding bone morphogenic receptor 2 (BMPR2). The latest examination of the right heart catheterization (RHC) demonstrated pulmonary artery pressure (PAP) values of 43/23 (mean 32) mmHg, right atrial pressure (RAP) of 6 mm Hg, and pulmonary capillary wedge pressure (PCWP) of 8 mm Hg on treatment with bosentan (125 mg/d) and intravenous epoprostenol (43 ng/kg/min). She was clinically stable (World Health Organization (WHO) functional class II). During the initial examination, her best‐corrected visual acuity was 1.2 in the right eye and 0.06 in the left eye. Intraocular pressure was 15 mm Hg in the right eye and 28 mm Hg in the left eye. Slit‐lamp examination revealed bilaterally dilated port‐wine‐colored episcleral vessels, which had been present since when she was in her 20s (Figure 1). Fundus examination revealed optic atrophy in the left eye.
Figure 1

Slit‐lamp photographs show bilaterally dilated port‐wine‐stained episcleral vessels in a 51‐year‐old woman

Slit‐lamp photographs show bilaterally dilated port‐wine‐stained episcleral vessels in a 51‐year‐old woman When we examined her 25‐year‐old son who is also diagnosed with HPAH, we similarly observed bilaterally dilated port‐wine‐colored episcleral vessels (Figure 2). His latest examination of the RHC demonstrated PAP values of 51/26 (mean 34) mm Hg, RAP of 4 mm Hg, and PCWP of 4 mm Hg on treatment with macitentan (10 mg/d), tadalafil (40 mg/d), and intravenous epoprostenol (98.2 ng/kg/min). He was clinically stable (WHO functional class II).
Figure 2

Slit‐lamp photographs of her 25‐year‐old son

Slit‐lamp photographs of her 25‐year‐old son Heritable pulmonary arterial hypertension is a rare, fatal, autosomal dominant disease in which idiopathic obliteration of the pulmonary arterial capillaries results in a right heart failure. Only few cases with pulmonary arterial hypertension (PAH) and ocular manifestations of the anterior segment have been previously reported.1, 2 In particular, there was only one case report that PAH was diagnosed via its ophthalmic features.1 Their clinical findings are similar to those in our cases. We were able to rule out any conditions known to cause dilated episcleral vessels, such as venous obstruction and arteriovenous shunts. Although the both cases were well managed by medications, we suggest that PAH‐induced elevation of venous pressure contributed to episcleral vessels dilation. In addition, we speculate that increased episcleral venous pressure might inhibit normal aqueous outflow and increase the intraocular pressure in her left eye. However, the reason why it occurred on one side is unknown. Although this present finding that was already diagnosed as PAH, we emphasize that symmetrically dilated port‐wine‐colored episcleral vessels may be observed in patients with a more common PAH sequela and should be considered in the differential diagnosis of the red eye. Accumulation of reports may be needed.

CONFLICT OF INTEREST

The authors have stated explicitly that there are no conflicts of interest in connection with this article.
  3 in total

1.  Primary pulmonary arterial hypertension diagnosed via its ophthalmic features in an adult: diagnosis and therapeutic challenges.

Authors:  Céline Faure; Sophie Miocque; Laurent Fleury; Matthieu P Robert
Journal:  Br J Ophthalmol       Date:  2010-09-18       Impact factor: 4.638

2.  Familial primary pulmonary hypertension and associated ocular findings.

Authors:  B R Saran; A J Brucker; F Bandello; C Verougstraete
Journal:  Retina       Date:  2001       Impact factor: 4.256

3.  Bilaterally dilated episcleral vessels in patients with heritable pulmonary arterial hypertension.

Authors:  Meri Watanabe; Shinji Makino; Hiroto Obata
Journal:  J Gen Fam Med       Date:  2017-06-01
  3 in total
  5 in total

1.  Anatomic, genetic and functional properties of the retinal circulation in pulmonary hypertension.

Authors:  Nils P Nickel; Elya A Shamskhou; Moataz A Razeen; David F Condon; Louise A Messentier Louro; Alfredo Dubra; Yaping J Liao; Roham T Zamanian; Ke Yuan; Vinicio A de Jesus Perez
Journal:  Pulm Circ       Date:  2020-05-04       Impact factor: 3.017

Review 2.  Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension.

Authors:  Nils P Nickel; Ke Yuan; Peter Dorfmuller; Steeve Provencher; Yen-Chun Lai; Sebastien Bonnet; Eric D Austin; Carl D Koch; Alison Morris; Frédéric Perros; David Montani; Roham T Zamanian; Vinicio A de Jesus Perez
Journal:  Am J Respir Crit Care Med       Date:  2020-01-15       Impact factor: 21.405

3.  Bilateral Episcleral Corkscrew Vessels: Expedition into the Unknown - Case Report.

Authors:  Carolina Madeira; Gonçalo Alves; Gonçalo Godinho; Jorge Meira; Vítor Leal; Manuel Falcão; Fernando Falcão-Reis; João Barbosa Breda
Journal:  Case Rep Ophthalmol       Date:  2022-02-24

4.  Bilaterally dilated episcleral vessels in patients with heritable pulmonary arterial hypertension.

Authors:  Meri Watanabe; Shinji Makino; Hiroto Obata
Journal:  J Gen Fam Med       Date:  2017-06-01

5.  OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY FINDINGS OF MICROVASCULAR AND NEURAL CHANGES IN PRIMARY PULMONARY HYPERTENSION.

Authors:  Simin Gu; Zijing Li; Yichi Zhang; Yingmei Liu; Peng Zeng; Rui Zeng; Wenhui Wang; Jianhui Xiao
Journal:  Retina       Date:  2021-04-01       Impact factor: 3.975

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.